Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

• Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
• Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
• Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
• Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
• Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
• Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.

Please see accompanying full Prescribing Information.